J Korean Med Sci.  2009 Dec;24(6):1078-1082. 10.3346/jkms.2009.24.6.1078.

Long-term Effectiveness and Tolerability of Topiramate in Children with Epilepsy under the Age of 2 Years: 4-Year Follow-up

• Kim JM
• Kwon S
• Seo HE
• Choe BH
• Cho MH
• Park SP

• KMID: 1783136
• DOI: http://doi.org/10.3346/jkms.2009.24.6.1078

Abstract

This is a long-term, open label, observational study aimed to broaden our clinical experiences in managing infants and toddlers with epilepsy. The long-term retention rate and side effects of topiramate (TPM) in them were evaluated and compared with carbamazepine (CBZ). A total of 146 children were involved in the study (TPM=41, CBZ=105). The retention rates at 24 , 36, and 48 months were 46.3%, 34.1%, 26.8% for TPM and 36.2%, 23.8%, 13.3% for CBZ, respectively. At 6 months after starting antiepileptic drugs (AED), the seizure freedom or clinical efficacy (seizure reduction rate more than 50 percent) were 73.2% for TPM and 62.9% for CBZ. The major side effects led to discontinuation included psychomotor slowing, poor oral intake from TPM and sleepiness and skin rash from CBZ. TPM was discontinued due to side effects in one case (2.4%) and lack of efficacy in five cases (12.2%), whereas CBZ was discontinued due to lack of efficacy (22.9%) and side effects (6.7%). As compared with CBZ, TPM showed the same long-term retention rate in children under the age of 2 yr, and no serious side effects. It is therefore concluded that TPM can be considered as a major AED for treating children with epilepsy under the age of 2 yr.

Keyword

Topiramate; Carbamazepine; Treatment Outcome; Adverse Effects

MeSH Terms

Anticonvulsants/adverse effects/*therapeutic use
Carbamazepine/adverse effects/therapeutic use
Child
Child, Preschool
Epilepsy/*drug therapy
Female
Follow-Up Studies
Fructose/adverse effects/*analogs & derivatives/therapeutic use
Humans
Infant
Male
Treatment Outcome

Figure

• 

  Fig. 1 Proportion of patients stayed on the initial AED at 24, 36, and 48 months. In the CBZ group, the proportion of patients kept on CBZ was 40.4%, 26.6%, and 14.9% at 24, 36, 48 months, respectively, and 47.7%, 31.8%, and 25.0% in the TPM groups. TPM tends to be continued in higher proportion of patients, but is not statistically different from CBZ. CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.

• 

  Fig. 2 Cumulative survival of topiramate (TPM) and carbamazepine (CBZ). The retention rates of TPM and CBZ were compared over 48 months or longer. TPM seemed to have a better retention rate, but was not significantly different from CBZ.

• 

  Fig. 3 Comparative efficacy between CBZ and TPM. At 6 months after starting the antiepileptic drug, 58.5% in the TPM group and 54.3% in the CBZ group became seizure free and the average monthly seizure frequency was decreased by 50% or more in 14.6% of the TPM group and 8.6% of the CBZ group respectively. The findings suggest that TPM is as efficacious as CBZ. Grade A, seizure freedom; Grade B, seizure reduction of average monthly frequency ≥50%; Grade C, seizure reduction of average monthly frequency 25-50%; Grade D, seizure reduction of average monthly frequency ≤25%; Grade E, no improvement in seizures; Grade F, worsening of seizures. CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.

• 

  Fig. 4 Adverse events of TPM (A) and CBZ (B). There were 12 events of side effects in 10 of 41 patients treated with TPM. In CBZ treated patients, there were 21 events of side effects in 18 of 105 patients. The most common adverse events were CNS-related in both groups and anhidrosis was another noticeable adverse event in the TPM group. CBZ, carbamazepine; TPM, topiramate.

• 

  Fig. 5 The main reason of discontinuation of AEDs. The leading causes were lack of efficacy (12.2% for TPM, 22.9% for CBZ) and adverse events (2.4% for TPM, 6.7% for CBZ). Others included deaths from acute illnesses, the poor compliance and so on. No statistically significant difference was noted between two groups. CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.

Reference

1. Aicardi J. Risks and benefits of new antiepileptic agents in children. Rev Neurol. 2000. 31:376–381.

2. Bourgeois BF. Pharmacokinetics and pharmacodynamics of topiramate. J Child Neurol. 2000. 15:Suppl 1. S27–S30.

3. Bebin M. Pediatric partial and generalized seizures. J Child Neurol. 2002. 17:Suppl 1. S65–S69.

4. Blumkin L, Lerman-Sagie T, Houri T, Gilad E, Nissenkorn A, Ginsberg M, Watemberg N. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol. 2005. 20:239–241.

5. Bootsma HP, Aldenkamp AP, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia. 2006. 47:Suppl 2. 24–27.

6. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol. 2000. 15:Suppl 1. S7–13.

7. Waugh J, Goa KL. Topiramate: as monotherapy in newly diagnosed epilepsy. CNS Drugs. 2003. 17:985–992.

8. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm. 1998. 55:554–562.

9. Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs. 2001. 3:293–319.

10. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004. 75:75–79.

11. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003. 107:165–175.

12. Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. J Child Neurol. 2007. 22:302–306.

13. Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999. 20:339–344.

14. Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, Motte J, Bourgeois M, Arzimanoglou A, Dulac O, Chiron C. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003. 53:225–232.

15. Mikaeloff Y, Rey E, Soufflet C, d'Athis P, Echenne B, Vallee L, Bouhours P, Grinspan A, Dulac O, Pons G, Chiron C. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia. 2004. 45:1448–1452.

16. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol. 2007. 9:256–267.

17. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007. 16:296–304.

18. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand. 2006. 114:157–168.

19. Bootsma HP, Coolen F, Aldenkamp AP, Arends J, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2004. 5:380–387.

20. Moreland EC, Griesemer DA, Holden KR. Topiramate for intractable childhood epilepsy. Seizure. 1999. 8:38–40.

21. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure. 2000. 9:137–141.

22. Voronkova KV, Pylaeva OA, Petrukhin AS. Efficacy of topiramate (Topamax) in epileptic patients of different ages. Neurosci Behav Physiol. 2007. 37:547–551.

23. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000. 9:590–594.

24. Zou LP, Lin Q, Qin J, Cai FC, Liu ZS, Mix E. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol. 2008. 31:86–92.

25. Nieto-Barrera M, Nieto-Jimenez M, Candau R, Ruiz del Portal L. Anhidrosis and hyperthermia associated with treatment with topiramate. Rev Neurol. 2002. 34:114–116.

26. Mukhin K, Glukhova L, Petrukhin AS, Mironov MB, Sobornova AM. Topamax in monotherapy of epilepsy. Zh Nevrol Psikhiatr Im S S Korsakova. 2004. 104:35–40.